SCHEMBL24282829

SCHEMBL24282829

CCOC(O)C(NC(=O)OCc1ccccc1)c1ccc(OC(=O)CCS(=O)(=O)OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
ACHE P22303 4/20 0.43
ATM Q13315 1/20 0.40
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KLK1 P06870 1/20 0.37
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2D6 P10635 1/20 0.36
MMP13 P45452 1/20 0.36
MAPT P10636 1/20 0.36
ELANE P08246 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21669236 0.92 CA1 (0.43) CA1CA2ACHEATMCTSL
SCHEMBL21669233 0.91 CA1 (0.43) CA1CA2ACHEATMCTSL
SCHEMBL21669256 0.90 CA1 (0.45) CA1CA2ACHEATMCTSL
SCHEMBL21669248 0.87 TRPM8 (0.45) ATMCTSLCTSSALDH1A1
SCHEMBL24282722 0.84 KMT2A (0.39) MEN1KMT2AALDH1A1MAPT
SCHEMBL21669239 0.83 PPARG (0.38) CA1CA2CTSSMEN1KMT2A
SCHEMBL21669244 0.83 CA1 (0.44) CA1CA2ACHEATMCTSL
SCHEMBL21669313 0.80 TRPM8 (0.47) ATMCTSLCTSSALDH1A1
SCHEMBL21669234 0.80 TRPM8 (0.48) ATMCTSLCTSSALDH1A1
SCHEMBL21669349 0.79 KMT2A (0.37) MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 CA1 713/4885CA2 2469/4885ACHE 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.